Mendelian randomization and clinical trial evidence supports TYK2 inhibition as a therapeutic target for autoimmune diseases
Year: 2023
Type: review
Study design: Observational Study
Abstract: BACKGROUND: To explore the associations of genetically proxied TYK2 inhibition with a wide range of disease outcomes and biomarkers to identify therapeutic repurposing opportunities, adverse effects, and biomarkers of efficacy. METHODS: The loss-of-function missense variant rs34536443 in TYK2 gene was used as a genetic instrument to proxy the effect of TYK2 inhibition. A phenome-wide Mendelian randomization (MR) study was conducted to explore the associations of genetically-proxied TYK2 inhibition with 1473 disease outcomes in UK Biobank (N = 339,197). Identified associations were examined for replication in FinnGen (N = 260,405). We further performed tissue-specific gene expression MR, colocalization analyses, and MR with 247 blood biomarkers. A systematic review of randomized controlled trials (RCTs) on TYK2 inhibitor was performed to complement the genetic evidence. FINDINGS: PheWAS-MR found that genetically-proxied TYK2 inhibition was associated with lower risk of a wide range of autoimmune diseases. The associations with hypothyroidism and psoriasis were confirmed in MR analysis of tissue-specific TYK2 gene expression and the associations with systemic lupus erythematosus, psoriasis, and rheumatoid arthritis were observed in colocalization analysis. There were nominal associations of genetically-proxied TYK2 inhibition with increased risk of prostate and breast cancer but not in tissue-specific expression MR or colocalization analyses. Thirty-seven blood biomarkers were associated with the TYK2 loss-of-function mutation. Evidence from RCTs confirmed the effectiveness of TYK2 inhibitors on plaque psoriasis and reported several adverse effects. INTERPRETATION: This study supports TYK2 inhibitor as a potential treatment for psoriasis and several other autoimmune diseases. Increased pharmacovigilance is warranted in relation to the potential adverse effects. FUNDING: None.
Source: EBioMedicine
Institutions: Karolinska Institutet, Second Affiliated Hospital of Zhejiang University, Zhejiang University, University of Edinburgh, Zhengzhou University, Westlake University, Fudan University, State Key Laboratory of Genetic Engineering, Greater Bay Area Institute of Precision Medicine, University of Cambridge, MRC Biostatistics Unit, Imperial College London, Medical Research Council, Edinburgh Cancer Research, Institute of Genetics and Cancer, Uppsala University
Language: English
Subfield: Genetics
Domain: Life Sciences
Open Access status: gold
Estimated APC paid: $5,000
Funders: Cancer Research UK, National Institute for Health and Care Research, British Heart Foundation, Imperial College London, University of London, National Natural Science Foundation of China, Cancerfonden, Hjärt-Lungfonden, Vetenskapsrådet, St. George's, University of London, Science Fund for Distinguished Young Scholars of Zhejiang Province
Awards: Research Excellence (round 3), G1801186217, G2755244757, G2818165094, Mendelian randomization approach to determine the causal role of potential risk factors for cardiovascular disease, G5204857013, G5646524191, G5684723974, G5993281984, G6028985673, G6265702644, G6882539308, G7362465939, G7363276477, G7706052761, G8592617908, G8771004808, G906748959
OpenAlex ID: W4321767932
